Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S. Tura, P. Mazza, F. Gherlinzoni, P. L. Zinzani, G. Poletti, G. Visani, R. M. Lemoli, M. Cavo, P. Galieni, C. Tassi, R. Zanchini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

Original languageEnglish
Pages (from-to)123-125
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 1989

Fingerprint

Alkylating Agents
Non-Hodgkin's Lymphoma
Toxicity
Phlebitis
Chemotherapy
Alopecia
Liver
Nausea
Vomiting
Diarrhea
Fever
Kidney
Drug Therapy
Pharmaceutical Preparations
ambamustine
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Tura, S., Mazza, P., Gherlinzoni, F., Zinzani, P. L., Poletti, G., Visani, G., ... Zanchini, R. (1989). Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemotherapy and Pharmacology, 23(2), 123-125. https://doi.org/10.1007/BF00273532

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. / Tura, S.; Mazza, P.; Gherlinzoni, F.; Zinzani, P. L.; Poletti, G.; Visani, G.; Lemoli, R. M.; Cavo, M.; Galieni, P.; Tassi, C.; Zanchini, R.

In: Cancer Chemotherapy and Pharmacology, Vol. 23, No. 2, 02.1989, p. 123-125.

Research output: Contribution to journalArticle

Tura, S, Mazza, P, Gherlinzoni, F, Zinzani, PL, Poletti, G, Visani, G, Lemoli, RM, Cavo, M, Galieni, P, Tassi, C & Zanchini, R 1989, 'Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas', Cancer Chemotherapy and Pharmacology, vol. 23, no. 2, pp. 123-125. https://doi.org/10.1007/BF00273532
Tura, S. ; Mazza, P. ; Gherlinzoni, F. ; Zinzani, P. L. ; Poletti, G. ; Visani, G. ; Lemoli, R. M. ; Cavo, M. ; Galieni, P. ; Tassi, C. ; Zanchini, R. / Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. In: Cancer Chemotherapy and Pharmacology. 1989 ; Vol. 23, No. 2. pp. 123-125.
@article{b66007d5796e4ddd85ab95aeb80249c1,
title = "Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas",
abstract = "In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57{\%}) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.",
author = "S. Tura and P. Mazza and F. Gherlinzoni and Zinzani, {P. L.} and G. Poletti and G. Visani and Lemoli, {R. M.} and M. Cavo and P. Galieni and C. Tassi and R. Zanchini",
year = "1989",
month = "2",
doi = "10.1007/BF00273532",
language = "English",
volume = "23",
pages = "123--125",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

AU - Tura, S.

AU - Mazza, P.

AU - Gherlinzoni, F.

AU - Zinzani, P. L.

AU - Poletti, G.

AU - Visani, G.

AU - Lemoli, R. M.

AU - Cavo, M.

AU - Galieni, P.

AU - Tassi, C.

AU - Zanchini, R.

PY - 1989/2

Y1 - 1989/2

N2 - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

AB - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

UR - http://www.scopus.com/inward/record.url?scp=0024271402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024271402&partnerID=8YFLogxK

U2 - 10.1007/BF00273532

DO - 10.1007/BF00273532

M3 - Article

C2 - 2910510

AN - SCOPUS:0024271402

VL - 23

SP - 123

EP - 125

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -